PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

International IP counsel

We understand the complexities of navigating the jurisdictional differences in core markets. We offer expert European patent advice to help you and your clients realise your IP strategy. We also strongly believe in future-proofing drafts to ensure multijurisdictional protection is not only achievable, but fully aligned with the commercial strategy. By keeping a finger on the pulse of fast-paced legal developments, we are perfectly positioned to help you navigate European IP challenges and opportunities.

European patent strategy

Europe remains a core market for pharmaceutical companies. As highly experienced European patent attorneys we provide tailored drafting and prosecution strategies aligned with your client’s commercial objectives. Our expertise enables us to recommend approaches for expediting prosecution, minimising expenses, or securing meaningful and robust protection against potential infringements. We excel at navigating the evolving landscape of pharmaceutical IP case law and can guide your clients through recent developments in second medical use, antibodies, polymorphs, and cell therapy patenting. Additionally, we offer guidance on managing post-published data, description modifications, and establishing proper basis for claim amendments within the European framework.

European regulatory environment

Patent protection typically forms just one element of your client’s comprehensive market strategy in Europe. We provide insights on the broader regulatory landscape, including EU clinical trial disclosure requirements, Brexit implications, data and market exclusivity periods, and how these mechanisms interact with patent systems throughout Europe to maximise protection and commercial advantage.

EPO oppositions and appeals

A granted European patent can be challenged centrally at the EPO, in every designated state at once, but only within nine months of grant. Where your clients need to clear a competitor’s European patent from their path to market, or to defend their own, we act for them in EPO oppositions and appeals, working alongside you as their lead counsel. We assess quickly whether an opposition is likely to succeed, and build the prior art, priority, sufficiency and added matter arguments. When your clients’ own patents are opposed, we prepare auxiliary requests that protect the commercially important claims, and we represent them before the Boards of Appeal. We also coordinate the European proceedings with challenges in the US and other markets, so that the arguments, evidence and amendments in one forum support your clients’ position in the others.

Fractional IP counsel

Why fractional IP counsel for your clients? When your clients need senior IP leadership in Europe, our fractional IP counsel model can place a named senior patent attorney inside their team as an extension of your own service. Our patent directors bring the real-world industry experience that you only get working in-house, and work alongside you as lead counsel rather than competing with you. Our own AI tools, developed by our attorneys specifically for pharma and biotech IP, let us turn European office actions around quickly and in depth, with the case law and the habits of the EPO built in, while our attorneys make the judgement calls. With our European team behind them, they provide a continuity that a lone consultant cannot, with a global strategic approach that fits the strategy you have set.

Fractional IP counsel
Evolve AI
Pharma IP Toolkit

Read more

Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025, we review the most impactful decisions of the year relating to clinical-stage inventions. 
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Divergence between the UPC and EPO on claim interpretation and description definitions (Agfa v Gucci, UPC_CFI_278/2023)

  • 12th August 2025
A new ruling in Agfa v Gucci reveals a split between the UPC and the EPO on claim interpretation, with the UPC using a patent’s own ‘lexicon’ to narrow a claim, a decision with major implications for patent holders in Europe.
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Don’t shoot yourself in the foot: European file history in US patent claim interpretation (K-fee v Nespresso)

  • 1st February 2024
This post is based on a previous article on IPKat. In the US, the principle of file wrapper estoppel is well established. Submissions made in US patent prosecution may be highly influential for claim interpretation post-grant. Additionally, as recently highlighted in K-fee v Nespresso (Case No. 22-2042, Fed. Cir. Dec. 26, 2023), file wrapper estoppel in the US does not…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

US Supreme Court decision in Amgen v Sanofi: The European Perspective

  • 1st June 2023
This post is based on a previous article on IPKat. The US Supreme Court recently ruled in the high profile Amgen versus Sanofi patent dispute. Agreeing with the Federal Circuit (No. 20-1074, Fed. Cir. 2021), the Supreme Court found Amgen’s function and epitope defined PCSK9 antibody patents to lack enablement (Amgen Inc v Sanofi, No. 21-757). The US…
View more Insights

Evolve Intellectual Property is a growing firm, with an excellent reputation.

IAM Patent 1000 logo

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

IP Stars from Managing IP logo

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice